Reni Benjamin

H.C. Wainwright Reiterates Buy On Celsion Following Release Of 3Q14 Results

In a research report published yesterday, H.C.

Editor Ben Weinberg — November 13, 2014, 1:13 PM EDT

TG Therapeutics Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note issued yesterday, H.C.

Editor Ben Weinberg — November 13, 2014, 12:34 PM EDT

H.C. Wainwright Reiterates Buy On OXiGENE Following 3Q14 Results

In a research note published this morning, H.C.

Editor Ben Weinberg — November 13, 2014, 11:36 AM EDT

Pluristem Represents An Undervalued Player With Upside For The Long-Term Investor, Says H.C. Wainwright

In a research note released today, H.C.

Editor Ben Weinberg — November 11, 2014, 2:59 PM EDT

H.C. Wainwright Reiterates Buy On Oxigene Following GOG Announcement On Zybrestat Avastin Combination Data

In a research report released this morning, H.C.

Editor Ben Weinberg — November 11, 2014, 2:30 PM EDT

H.C. Wainwright Reiterates Buy On Spectrum Pharma Following 3Q14 Results

In a research note issued today, H.C.

Editor Ben Weinberg — November 7, 2014, 9:58 PM EDT

Oncothyreon Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright

In a research note released today, H.C.

Editor Ben Weinberg — November 7, 2014, 8:57 PM EDT

H.C. Wainwright Reiterates Buy On Keryx Following 3Q14 Results

In a research report released today, H.C.

Editor Ben Weinberg — November 7, 2014, 8:16 PM EDT

Shares Of Ariad Are Undervalued And Present Upside, Says H.C. Wainwright

In a research report published today, H.C.

Editor Ben Weinberg — November 6, 2014, 5:23 PM EDT

H.C. Wainwright Reiterates Buy On La Jolla As ASN Abstract Highlights Efficacy In Diabetics

In a research report issued today, H.C.

Corey Williams — October 24, 2014, 11:51 AM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts